Edition:
United States

Vascular Biogenics Ltd (VBLT.OQ)

VBLT.OQ on NASDAQ Stock Exchange Global Market

6.60USD
3:59pm EST
Change (% chg)

$0.00 (+0.00%)
Prev Close
$6.60
Open
$6.60
Day's High
$6.60
Day's Low
$6.50
Volume
5,352
Avg. Vol
53,648
52-wk High
$9.05
52-wk Low
$3.95

Chart for

About

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company's program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly... (more)

Overall

Beta: --
Market Cap(Mil.): $196.18
Shares Outstanding(Mil.): 29.72
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 186.11 15.67
EPS (TTM): -- -- --
ROI: -- -11.32 34.62
ROE: -- -35.69 16.00

BRIEF-VBL therapeutics prices 2.5 mln ordinary share offering

* VBL Therapeutics prices 2.5 million ordinary share offering

Nov 17 2017

BRIEF-VBL Therapeutics announces proposed public offering of 2.5 mln shares of ordinary shares

* VBL Therapeutics announces proposed public offering of 2.5 million shares of ordinary shares Source text for Eikon: Further company coverage:

Nov 16 2017

BRIEF-VBL therapeutics Q3 loss per share $0.24

* VBL Therapeutics announces third quarter 2017 financial results

Nov 14 2017

BRIEF-VBL Therapeutics and Nanocarrier signs agreement for VB-111 in Japan

* VBL Therapeutics and Nanocarrier Co Ltd sign exclusive agreement for VB-111 in Japan

Nov 06 2017

BRIEF-VBL THERAPEUTICS OPENS NEW GENE THERAPY MANUFACTURING PLANT, HEADQUARTERS

* VBL THERAPEUTICS CELEBRATES OPENING OF ITS NEW GENE THERAPY MANUFACTURING PLANT AND COMPANY HEADQUARTERS

Oct 23 2017

BRIEF-VBL Therapeutics says VB-111 given orphan drug designation in Europe

* VBL Therapeutics announces orphan drug designation for VB-111 in Europe

Oct 20 2017

BRIEF-Vascular Biogenics reports Q2 loss per share $0.18

* Vbl therapeutics announces second quarter 2017 financial results

Aug 14 2017

BRIEF-VBL Therapeutics provides update on long-term survival in phase 2 trials of patients with multiple tumor types

* VBL Therapeutics provides update on long-term survival in phase 2 trials of patients with multiple tumor types

Jun 19 2017

BRIEF-Vascular Biogenics appoints Dr. Corinne Epperly as U.S. Chief Operating Officer

* VBL Therapeutics announces appointment of Dr. Corinne Epperly as U.S. Chief Operating Officer Source text for Eikon: Further company coverage:

Jun 15 2017

Earnings vs. Estimates